Abstract
The emergence of the SARS-CoV-2 virus at the end of 2019 and the ensuing pandemic marked an inflection point in vaccine development strategies and other immunobiologicals. It became evident that there is a need to be prepared for emerging diseases with ready-to-deploy development platforms to combat emerging or re-emerging diseases.Immunogenicity and safety trials for immunobiologicals ar…